Subscribe To
ELVN / Enliven Therapeutics: Preclinical Company With Interesting Value Proposition
Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has raised $165 million in a private placement to fund its pipeline, which includes two phase 1 candidates. ELVN-001 targets chronic myeloid leukemia and shows promise in preclinical tests, while ELVN-002 is a selective HER2 inhibitor with potential in HER2-driven cancers.
Read More
Content Topics
Enliven
Therapeutics
Preclinical
Company
With
Interesting
Therapeutics
Proposition
Stock
ELVN
Posted: Aug 18 2023, 12:57
Author Name: Seeking Alpha
Views: 112547
ELVN News
By Seeking Alpha
August 18, 2023
Enliven Therapeutics: Preclinical Company With Interesting Value Proposition
Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has more_horizontal